Cardiovascular Pharmacogenomics explores how genetic variation influences medication response, helping clinicians personalize therapy for safer, more effective cardiovascular care. This session examines the genetic factors affecting metabolism, efficacy, and adverse reactions to drugs such as clopidogrel, statins, beta-blockers, warfarin, direct oral anticoagulants, and antihypertensives. As personalized medicine rises, demand for a scientific cardiology conference increases across cardiology, genetics, and pharmacology communities.

Participants will learn how genetic testing reveals CYP450 variants, transporter polymorphisms, and receptor differences that affect drug activation, metabolism, or clearance. Case discussions illustrate treatment failures, bleeding risks, statin intolerance, and resistant hypertension attributable to genetic factors. The session covers guidelines for when to test, how to interpret results, and how to integrate findings into prescribing decisions.

A major focus is applying pharmacogenomic-guided therapy in real-world settings—pre-PCI antiplatelet selection, DOAC metabolism assessment, statin safety optimization, and individualized anticoagulation. Participants will also explore how polygenic risk scores, multi-omics databases, and machine learning may enhance future decision-making.

The session concludes with implementation strategies for hospitals and clinics, including EHR integration, laboratory partnerships, and workflow standardization. By the end, attendees will understand how pharmacogenomics bridges precision medicine and cardiovascular therapeutics.